Avacta's Faridoxorubicin Shows Promising Phase 1a Results in Salivary Gland Cancer

Avactas Faridoxorubicin demonstrates significant efficacy in treating salivary gland cancer, with a disease control rate of 91% and no severe toxicity observed, challenging current oncology standards.

• In a Phase 1a trial, patients with salivary gland cancer showed promising results with a median progression free survival (PFS) not yet reached, indicating a potential doubling of benchmark PFS.
• Despite administering doses up to 385 mg/m² of Faridoxorubicin, which is approximately four times the conventional doxorubicin dose, no maximum tolerated dose was reached, highlighting its safety profile.
• No severe cardiac toxicity was reported even at cumulative doses of 550 mg/m², making Faridoxorubicin a potentially safer alternative in oncology compared to traditional cancer treatments.